Author:
Paek Young Min,Lee Ji Sung,Park Hong-Kyun,Cho Yong-Jin,Bae Hee-Joon,Kim Beom Joon,Park Jong-Moo,Lee Soo Joo,Cha Jae-Kwan,Park Tai Hwan,Lee Kyung Bok,Lee Jun,Lee Byung-Chul,Kim Joon-Tae,Kim Dong-Eog,Shin Dong-Ick,Kim Wook-Joo,Sohn Sung-Il,Choi Jay Chol,Hong Keun-Sik
Subject
Physiology (medical),Neurology (clinical),Neurology,General Medicine,Surgery
Reference27 articles.
1. The National institute of neurological disorders and stroke rt-PA stroke study group;Tissue plasminogen activator for acute ischemic stroke;N Engl J Med,1995
2. Stroke treatment with alteplase given 3.0–4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial;Bluhmki;Lancet Neurol,2009
3. Alteplase for acute ischemic stroke: outcomes by clinically important subgroups in the Third International Stroke Trial;Lindley;Stroke,2015
4. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials;Emberson;Lancet,2014
5. group ISTc, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet 2012; 379: 2352-2363.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献